Drug Detail:Japanese encephalitis vaccine (monograph) (Ixiaro)
Drug Class:
Usual Adult Dose for Japanese Encephalitis Virus Prophylaxis
Primary Series: Two 0.5 mL doses intramuscularly 28 days apart
Booster Dose: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.
Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.
Usual Pediatric Dose for Japanese Encephalitis Virus Prophylaxis
Primary Series:
3 years of age and older: Two 0.5 mL doses intramuscularly 28 days apart
2 months to less than 3 years of age: Two 0.25 mL doses intramuscularly 28 days apart
Booster Dose:
17 years of age and older: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.
2 months to under 17 years: The safety and immunogenicity of a booster dose has not been evaluated.
Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Severe allergic reactions (e.g. anaphylaxis) to any of the ingredients or to any other Japanese encephalitis virus vaccine
- Consider an allergist referral for patients allergic to another Japanese encephalitis vaccine to determine if this vaccine is appropriate; uncertainty is possible as to which vaccine component lead to the allergic reaction.
Safety and efficacy have not been established in patients younger than 2 months.
To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Administer intramuscularly
- Do not administer intravenously, intradermally or subcutaneously
- Preferred sites for IM injection: The anterolateral aspect of the thigh in infants 2 to 11 months of age, the anterolateral aspect of the thigh or the deltoid muscle (if muscle mass is adequate) in children 1 to less than 3 years of age, or the deltoid muscle in individuals 3 years of age and older
Storage requirements:
- Refrigerate; do not freeze
- Store in the original packaging to protect from light.
